Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-27Clinical Trial Update: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 trial of oprozomib with pomalidomide and dexamethasone in adults with primary refractory or relapsed and refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) [Phase 1, Phase 2]
Phase 1/2 clinical trial exploring busulfan, melphalan, and escalating carfilzomib conditioning for autologous stem cell transplantation in …
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating avelumab with hypofractionated radiotherapy in relapsed/refractory multiple myeloma; study terminated with results …
-
CLINICAL_TRIALS trial_result · 2021-04-14Clinical Trial Update: Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM [Phase 3]
Phase 3 trial comparing lenalidomide versus placebo maintenance after induction therapy in newly diagnosed multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) [Phase 1]
Phase I study of MK-0683 in combination with bortezomib in multiple myeloma has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) [Phase 1]
Phase 1 study of pembrolizumab in combination with standard of care treatments for multiple myeloma was terminated; results posted in 2021.
-
FDA approval · 2021-03-31FDA Approved: SARCLISA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for SARCLISA (isatuximab) from Sanofi-Aventis U.S. LLC. The action signifies an expanded or updated …
-
FDA approval · 2021-03-18FDA Approved: SARCLISA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA lists a supplemental application for Sarclisa (isatuximab) from Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma [Phase 2]
Phase 2 clinical trial comparing F-18 FDG and C-11 acetate PET in multiple myeloma has completed with posted results.
-
FDA label_change · 2021-03-12FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approves a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) by Janssen Biotech, expanding its labeling …
-
FDA approval · 2021-03-10FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, resulting in an updated approval…
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment [Phase 3]
Phase 3 trial comparing pom-dex vs pom-cyclo-dex in multiple myeloma patients during lenalidomide maintenance; study terminated with posted …
-
FDA approval · 2021-03-09FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
The FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc., marking an expansion of its …
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) [Phase 2]
The National Cancer Institute’s MATCH subprotocol R Phase 2 trial is evaluating trametinib as a targeted therapy for cancers with BRAF genet…
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial investigating oprozomib with dexamethasone in combination with lenalidomide or oral cyclophosphamide for newly diagnosed mul…
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating melphalan and radiation therapy followed by lenalidomide in patients undergoing autologous stem cell transplant f…
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) [Phase 1]
Phase 1 study of pembrolizumab in combination with dinaciclib in hematologic malignancies was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells [Phase 2]
Phase 2 exploratory safety trial comparing G-CSF alone versus G-CSF plus plerixafor in multiple myeloma patients who may be poor mobilizers,…
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 study evaluating single-agent lenalidomide in older adults with newly diagnosed multiple myeloma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma [Phase 2]
Phase II trial evaluating meloxicam plus filgrastim in patients with multiple myeloma and non-Hodgkin's lymphoma has completed with results …
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A two-phase clinical trial evaluating pomalidomide and bendamustine with dexamethasone for relapsed or refractory multiple myeloma is report…
-
FDA approval · 2021-02-08FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), updating or expanding its labeling.
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis
A retrospective observational analysis of multiple myeloma patients in Brazil, completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) [Phase 2]
A Phase 2 MATCH-subprotocol Q trial evaluating ado-trastuzumab emtansine (T-DM1) for cancers with HER2 genetic changes; results were posted …
-
CLINICAL_TRIALS trial_result · 2021-02-01Clinical Trial Update: IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 trial comparing IXAZOMIB+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in adults with newly diagnosed multi…